Adrian Vella

List of Publications by Year
in descending order

125 papers	5,998 citations	81839 39 h-index	76872 74 g-index
150 all docs	150 docs citations	150 times ranked	6532 citing authors

#	Article	IF	Citations
1	Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and Hyperlipidemia. JAMA - Journal of the American Medical Association, 2013, 309, 2240.	3.8	655
2	Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4053-4059.	1.8	313
3	Secular Trends in the Presentation and Management of Functioning Insulinoma at the Mayo Clinic, 1987â€“2007. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1069-1073.	1.8	279
4	Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A_{1c}, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. JAMA - Journal of the American Medical Association, 2018, 319, 266.	3.8	224
5	Adrenal Hemorrhage: A 25-Year Experience at the Mayo Clinic. Mayo Clinic Proceedings, 2001, 76, 161-168.	1.4	194
6	Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes. Diabetes, 2007, 56, 1475-1480.	0.3	187
7	Effects of GLP-1 on appetite and weight. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 181-187.	2.6	182
8	The Oral Minimal Model Method. Diabetes, 2014, 63, 1203-1213.	0.3	169
9	Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 413-422.	5.5	163
10	Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. American Journal of Physiology - Renal Physiology, 2002, 282, G424-G431.	1.6	162
11	Use of a novel triple-tracer approach to assess postprandial glucose metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E55-E69.	1.8	158
12	Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding. Diabetes, 2001, 50, 1351-1362.	0.3	154
13	Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass. Diabetes, 2014, 63, 483-493.	0.3	123
14	Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 890-899.	3.7	123
15	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nature Communications, 2020, 11, 87.	5.8	118
16	Systemic and regional free fatty acid metabolism in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2001, 280, E1000-E1006.	1.8	114
17	Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. American Journal of Physiology - Renal Physiology, 2000, 278, G946-G951.	1.6	112
18	First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. Diabetes Care, 2018, 41, 2396-2403.	4.3	99

#	Article	IF	Citations
19	Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial. Diabetes Care, 2016, 39, 1510-1518.	4.3	79
20	Effects of Free Fatty Acids and Glycerol on Splanchnic Glucose Metabolism and Insulin Extraction in Nondiabetic Humans. Diabetes, 2002, 51, 301-310.	0.3	78
21	The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes. Diabetes, 2013, 62, 1094-1101.	0.3	78
22	Glucose metabolism during rotational shift-work in healthcare workers. Diabetologia, 2017, 60, 1483-1490.	2.9	76
23	Relationship Between Glycemic Control and Gastric Emptying in Poorly Controlled Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2015, 13, 466-476.e1.	2.4	75
24	MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia. European Journal of Endocrinology, 2017, 177, R37-R47.	1.9	71
25	GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1552-1563.	1.8	60
26	Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. JCI Insight, 2020, 5, .	2.3	60
27	The effect of dipeptidyl peptidaseâ€4 inhibition on gastric volume, satiation and enteroendocrine secretion in typeÂ2 diabetes: a doubleâ€blind, placeboâ€controlled crossover study. Clinical Endocrinology, 2008, 69, 737-744.	1.2	59
28	Application of Isotopic Techniques Using Constant Specific Activity or Enrichment to the Study of Carbohydrate Metabolism. Diabetes, 2009, 58, 2168-2174.	0.3	59
29	Mechanism of Action of DPP-4 Inhibitorsâ€"New Insights. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2626-2628.	1.8	59
30	Selective Arterial Calcium Stimulation With Hepatic Venous Sampling Differentiates Insulinoma From Nesidioblastosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4189-4197.	1.8	59
31	Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes. Diabetes Care, 2009, 32, 14-18.	4.3	58
32	Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E105-E121.	1.8	55
33	The effect of DPPâ€4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology, 2010, 73, 189-196.	1.2	54
34	Burden and management of type 2 diabetes in rural United States. Diabetes/Metabolism Research and Reviews, 2021, 37, e3410.	1.7	49
35	Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of Î²-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care, 2016, 39, 1602-1613.	4.3	47
36	Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Science Translational Medicine, 2019, 11, .	5.8	47

#	Article	IF	Citations
37	Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3718-e3729.	1.8	45
38	TCF7L2 Genotype and Î±-Cell Function in Humans Without Diabetes. Diabetes, 2016, 65, 371-380.	0.3	43
39	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine, 2020, 55, 102759.	2.7	43
40	Three hours of intermittent hypoxia increases circulating glucose levels in healthy adults. Physiological Reports, 2017, 5, e13106.	0.7	42
41	Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2013, 109, 669-675.	1.8	41
42	Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovascular Diabetology, 2019, 18, 22.	2.7	41
43	Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass. Diabetes, 2015, 64, 3104-3110.	0.3	40
44	Six and 12 Weeks of Caloric Restriction Increases Î² Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes. Journal of Nutrition, 2015, 145, 2046-2051.	1.3	40
45	What is type 2 diabetes?. Medicine, 2010, 38, 597-601.	0.2	39
46	A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clinical Endocrinology, 2012, 76, 212-219.	1.2	37
47	A model of GLP-1 action on insulin secretion in nondiabetic subjects. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E1115-E1121.	1.8	36
48	Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1. Diabetes, 2012, 61, 1082-1089.	0.3	36
49	A Review of the Pathophysiology and Management of Diabetes in Pregnancy. Mayo Clinic Proceedings, 2020, 95, 2734-2746.	1.4	36
50	What to do about the leaky gut. Gut, 2022, 71, 424-435.	6.1	34
51	The gastrointestinal tract and glucose tolerance. Current Opinion in Clinical Nutrition and Metabolic Care, 2004, 7, 479-484.	1.3	32
52	Genetics of type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 471-477.	1.3	31
53	The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion. Diabetes, 2017, 66, 2729-2737.	0.3	30
54	Endoscopic management of dumping syndrome after Roux-en-Y gastric bypass: a large international series and proposed management strategy. Gastrointestinal Endoscopy, 2020, 92, 91-96.	0.5	30

#	Article	IF	Citations
55	Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 589-598.	1.8	29
56	Impact of variant pancreatic arterialÂanatomy and overlap in regional perfusion on the interpretation of selective arterial calcium stimulation with hepatic venous sampling for preoperative localization of occult insulinoma. Surgery, 2015, 158, 162-172.	1.0	28
57	Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 314-319.	1.8	26
58	Pro-inflammatory Î² cell small extracellular vesicles induce Î² cell failure through activation of the CXCL10/CXCR3 axis in diabetes. Cell Reports, 2021, 36, 109613.	2.9	25
59	Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, Î²-Cell Function, and Glucose Metabolism in Nondiabetic Subjects. Diabetes, 2013, 62, 2752-2756.	0.3	24
60	Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. Diabetes Care, 2020, 43, 418-425.	4.3	23
61	Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E259-E266.	1.8	21
62	Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance. Diabetes, 2016, 65, 887-892.	0.3	21
63	Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor. World Journal of Surgery, 2020, 44, 2288-2294.	0.8	21
64	Comparison of benign and malignant insulinoma. American Journal of Surgery, 2021, 221, 437-447.	0.9	20
65	Biology of Activating Transcription Factor 4 (ATF4) and Its Role in Skeletal Muscle Atrophy. Journal of Nutrition, 2022, 152, 926-938.	1.3	20
66	A Model for the Estimation of Hepatic Insulin Extraction After a Meal. IEEE Transactions on Biomedical Engineering, 2016, 63, 1925-1932.	2.5	19
67	Model-Based Quantification of Glucagon-Like Peptide-1â€“Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge. Diabetes Technology and Therapeutics, 2016, 18, 39-46.	2.4	18
68	Pituitary Apoplexy. , 2001, 11, 282-288.		16
69	Deficient Glucagon Response to Hypoglycemia During a Mixed Meal in Total Pancreatectomy/Islet Autotransplantation Recipients. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1522-1529.	1.8	16
70	Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB). Metabolism: Clinical and Experimental, 2019, 93, 10-17.	1.5	16
71	National Differences in Remission of Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass Surgery-Subgroup Analysis of 2-Year Results of the Diabetes Surgery Study Comparing Taiwanese with Americans with Mild Obesity (BMI 30â€“35Âkg/m2). Obesity Surgery, 2017, 27, 1189-1195.	1.1	15
72	Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with Î² Cell Function. Metabolic Syndrome and Related Disorders, 2018, 16, 406-415.	0.5	15

#	Article	IF	Citations
73	Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opinion on Pharmacotherapy, 2008, 9, 1109-1119.	0.9	14
74	TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes. Expert Opinion on Investigational Drugs, 2019, 28, 741-747.	1.9	14
75	Diabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans. JCI Insight, 2020, 5, .	2.3	14
76	Fasting glucagon concentrations are associated with longitudinal decline of Î²-cell function in non-diabetic humans. Metabolism: Clinical and Experimental, 2020, 105, 154175.	1.5	14
77	Glucose tolerance and free fatty acid metabolism in adults with variations in TCF7L2 rs7903146. Metabolism: Clinical and Experimental, 2017, 68, 55-63.	1.5	13
78	Performance of individually measured vs populationâ€based <scp>C</scp>â€peptide kinetics to assess Î²â€cell function in the presence and absence of acute insulin resistance. Diabetes, Obesity and Metabolism, 2018, 20, 549-555.	2.2	13
79	Deficient Endogenous Glucose Production During Exercise After Total Pancreatectomy/Islet Autotransplantation. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3288-3295.	1.8	12
80	Pharmacogenetics for Type 2 Diabetes: Practical Considerations for Study Design. Journal of Diabetes Science and Technology, 2009, 3, 705-709.	1.3	11
81	What Can Diabetes-Associated Genetic Variation in TCF7L2 Teach Us About the Pathogenesis of Type 2 Diabetes?. Metabolic Syndrome and Related Disorders, 2018, 16, 383-389.	0.5	11
82	Measurement of Pulsatile Insulin Secretion: Rationale and Methodology. Metabolites, 2021, 11, 409.	1.3	11
83	Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4816-4824.	1.8	10
84	What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism?. Frontiers in Endocrinology, 2018, 9, 324.	1.5	10
85	A Hepatocyte FOXN3-Î± Cell Glucagon Axis Regulates Fasting Glucose. Cell Reports, 2018, 24, 312-319.	2.9	10
86	The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 305.	1.1	9
87	Regenerative Medicine in Diabetes. Mayo Clinic Proceedings, 2015, 90, 546-554.	1.4	9
88	Glucose Counterregulatory Hormones in the 72-Hour Fast. Endocrine Practice, 2003, 9, 115-118.	1.1	8
89	Malignant Adrenal Neoplasm Masquerading as Worrisome Adrenal Hemorrhage. Annals of Surgical Oncology, 2010, 17, 2710-2713.	0.7	8
90	Gastrointestinal Hormones and Gut Endocrine Tumors. , 2016, , 1701-1722.		8

#	Article	IF	Citations
91	Assessment of individual and standardized glucagon kinetics in healthy humans. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E71-E77.	1.8	8
92	Limitations of the fasting proinsulin to insulin ratio as a measure of Î²â€cell health in people with and without impaired glucose tolerance. European Journal of Clinical Investigation, 2021, 51, e13469.	1.7	8
93	Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above?. Diabetes, 2015, 64, 2324-2325.	0.3	6
94	Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 2, 83-90.	1.1	5
95	Predicting Diabetes Using Measures of Â-Cell Function. Diabetes, 2012, 61, 562-563.	0.3	5
96	Assessment of pulsatile insulin secretion derived from peripheral plasma C-peptide concentrations by nonparametric stochastic deconvolution. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E687-E694.	1.8	5
97	Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1702-1709.	1.8	5
98	Association of plasma ceramides with prevalent and incident type 2 diabetes mellitus in middle and older aged adults. Diabetes Research and Clinical Practice, 2021, 179, 108991.	1.1	5
99	Does Caloric Restriction Alone Explain the Effects of Roux-en-Y Gastric Bypass on Glucose Metabolism? Not by a Long Limb. Diabetes, 2013, 62, 3017-3018.	0.3	4
100	Eulogy for the Metabolic Clinical Investigator?. Diabetes, 2016, 65, 2821-2823.	0.3	4
101	A novel triple-tracer approach to assess postprandial protein turnover. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E469-E477.	1.8	4
102	Association between allelic variants in the glucagonâ€like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. Neurogastroenterology and Motility, 2020, 32, e13724.	1.6	4
103	Gastrointestinal Hormones and Gut Endocrine Tumors. , 2011, , 1697-1716.		4
104	Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in non-diabetic subjects. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E728-E736.	1.8	4
105	Hepatic Artery Embolization for Palliation of Symptomatic Hypoglycemia in Patients with Hepatic Insulinoma Metastases. Journal of the Endocrine Society, 2021, 5, bvab149.	0.1	3
106	Obstacles to Translating Genotype-Phenotype Correlates in Metabolic Disease. Physiology, 2017, 32, 42-50.	1.6	2
107	Exocrine and Endocrine Interactions in Cystic Fibrosis: A Potential Key to Understanding Insulin Secretion in Health and Disease?. Diabetes, 2017, 66, 20-22.	0.3	2
108	Walking a fine line between Î²-cell secretion and proliferation. Journal of Biological Chemistry, 2018, 293, 14190-14191.	1.6	2

#	Article	IF	Citations
109	Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance. Journal of the Endocrine Society, 2019, 3, 135-145.	0.1	2
110	A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery. Metabolic Syndrome and Related Disorders, 2020, 18, 406-412.	0.5	2
111	Endoscopic Treatments for Obesity. Endocrinology and Metabolism Clinics of North America, 2020, 49, 315-328.	1.2	2
112	The Effect of Diabetes-Associated Variation in TCF7L2 on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched. Metabolic Syndrome and Related Disorders, 2022, , .	0.5	2
113	Prandial Insulin and the Systemic Appearance of Meal-Derived Glucose in People With Type 1 Diabetes. Diabetes Care, 2008, 31, 2230-2231.	4.3	1
114	Common Genetic Variation Influences the Heterogeneity of Response to Oral Glucose. Current Diabetes Reports, 2010, 10, 249-251.	1.7	1
115	Risk Factors and Wellness Measures Associated with Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus in Hispanic Adults. Metabolic Syndrome and Related Disorders, 2021, 19, 180-189.	0.5	1
116	How should Secondary Causes of Diabetes be Excluded?. , 0, , 22-33.		1
117	The relationship between insulin and glucagon concentrations in <scp>nonâ€diabetic</scp> humans. Physiological Reports, 2022, 10, .	0.7	1
118	Detection and Diagnosis of Type 2 Diabetes. , 2008, , 75-83.		0
119	The Currency of Science. Metabolic Syndrome and Related Disorders, 2017, 15, 385-386.	0.5	0
120	Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function. Contemporary Clinical Trials Communications, 2018, 10, 94-99.	0.5	0
121	Letter to the Editor: â€œDefects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetesâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5106-5107.	1.8	0
122	Call for Special Issue Papers: Inflammation and Metabolic Disorders. Metabolic Syndrome and Related Disorders, 2021, 19, 191-191.	0.5	0
123	Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2009, 2, 83-90.	1.1	0
124	Tighten Your Belt! Banded Roux-en-Y Gastric Bypass for Diabetes Remission?. Diabetes Care, 2022, 45, 1495-1497.	4.3	0
125	Editorial Cycles and Continuity of Diabetes Care. Diabetes Care, 2022, 45, 1493-1494.	4.3	0